Ilene Weitz, MD, discusses research on several new therapies for paroxysmal nocturnal hemoglobinuria (PNH) with promising clinical impact presented at ASH 2024. The APPLY-PNH and APPOINT-PNH ...
A novel drug combination, improvements in quality of life, and breakthrough hemolysis control are among the clinical highlights in paroxysmal nocturnal hemoglobinuria (PNH) presented at the 2024 ...
Victor Bultó, president of Novartis in the US, said that the approval of Fabhalta “may mean that patients can reset their expectations of living with PNH.” Analysts at Jefferies have ...
Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback